JP Morgan Chase
MYGN icon

JP Morgan Chase’s Myriad Genetics MYGN Stock Holding History

JP Morgan Chase’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-101,200
Closed -$1.69M – 5171
2016
Q4 		$1.69M Buy
+101,200
New +$1.83M ﹤0.01% 3175
2015
Q1 		– Sell
-160,000
Closed -$5.45M – 4200
2014
Q4 		$5.45M Buy
+160,000
New +$5.68M ﹤0.01% 2357

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase's MYGN Position: Q2 2026 in Review

JP Morgan Chase reduced its Myriad Genetics (MYGN) stake by 78% in Q2 2026, selling an estimated $938K and leaving 57,221 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #5333.

JP Morgan Chase first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $24.3M in Q2 2021. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • JP Morgan Chase held 57,221 shares of Myriad Genetics worth $335K as of Q2 2026.
  • JP Morgan Chase sold 206,644 Myriad Genetics shares in Q2 2026, an estimated $938K.
  • Myriad Genetics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5333 holding.
  • JP Morgan Chase first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Myriad Genetics position peaked at $24.3M in Q2 2021.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.